Cargando…
L-Mesitran Foam: Evaluation of a New Wound Care Product
Chronic wounds are a health problem that has devastating consequences for patients and their quality of life. Often, chronic wounds are stuck in the inflammatory phase or burdened with an infection. Therefore, it is important to find alternative all-round wound care products that have both wound hea...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023218/ https://www.ncbi.nlm.nih.gov/pubmed/35464882 http://dx.doi.org/10.1155/2022/4833409 |
_version_ | 1784690291480985600 |
---|---|
author | Mthanti, Segametsi Mary-Jane Pelle, Gloria Cremers, Niels A. J. |
author_facet | Mthanti, Segametsi Mary-Jane Pelle, Gloria Cremers, Niels A. J. |
author_sort | Mthanti, Segametsi Mary-Jane |
collection | PubMed |
description | Chronic wounds are a health problem that has devastating consequences for patients and their quality of life. Often, chronic wounds are stuck in the inflammatory phase or burdened with an infection. Therefore, it is important to find alternative all-round wound care products that have both wound healing and antimicrobial activities. New wound care products are developed constantly, implementing the latest knowledge and advances in wound care. Honey-based wound care formulations and foam dressings are increasingly used in the clinic. L-Mesitran Foam is a novel product in which a foam dressing is precoated with medical-grade honey. Here, we describe our first experiences with L-Mesitran Foam in the clinic. In this case report, a 57-year-old woman with diabetes mellitus type 2 and hypertension presented with a chronic diabetic venous leg ulcer on her leg. Treatments over six months with different treatments, including povidone-iodine, silver dressings, and compression therapy, were ineffective and subsequently switched to L-Mesitran Foam. The dressing choice was based on the wound type and complied with the instructions for use. Wound healing progressed nicely on different aspects and led to complete healing on day 23. No side effects or pain was experienced during treatment. The presented case supports the safety and efficacy of L-Mesitran Foam and serves as a proof of concept. |
format | Online Article Text |
id | pubmed-9023218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90232182022-04-22 L-Mesitran Foam: Evaluation of a New Wound Care Product Mthanti, Segametsi Mary-Jane Pelle, Gloria Cremers, Niels A. J. Case Rep Dermatol Med Case Report Chronic wounds are a health problem that has devastating consequences for patients and their quality of life. Often, chronic wounds are stuck in the inflammatory phase or burdened with an infection. Therefore, it is important to find alternative all-round wound care products that have both wound healing and antimicrobial activities. New wound care products are developed constantly, implementing the latest knowledge and advances in wound care. Honey-based wound care formulations and foam dressings are increasingly used in the clinic. L-Mesitran Foam is a novel product in which a foam dressing is precoated with medical-grade honey. Here, we describe our first experiences with L-Mesitran Foam in the clinic. In this case report, a 57-year-old woman with diabetes mellitus type 2 and hypertension presented with a chronic diabetic venous leg ulcer on her leg. Treatments over six months with different treatments, including povidone-iodine, silver dressings, and compression therapy, were ineffective and subsequently switched to L-Mesitran Foam. The dressing choice was based on the wound type and complied with the instructions for use. Wound healing progressed nicely on different aspects and led to complete healing on day 23. No side effects or pain was experienced during treatment. The presented case supports the safety and efficacy of L-Mesitran Foam and serves as a proof of concept. Hindawi 2022-04-14 /pmc/articles/PMC9023218/ /pubmed/35464882 http://dx.doi.org/10.1155/2022/4833409 Text en Copyright © 2022 Segametsi Mary-Jane Mthanti et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Mthanti, Segametsi Mary-Jane Pelle, Gloria Cremers, Niels A. J. L-Mesitran Foam: Evaluation of a New Wound Care Product |
title | L-Mesitran Foam: Evaluation of a New Wound Care Product |
title_full | L-Mesitran Foam: Evaluation of a New Wound Care Product |
title_fullStr | L-Mesitran Foam: Evaluation of a New Wound Care Product |
title_full_unstemmed | L-Mesitran Foam: Evaluation of a New Wound Care Product |
title_short | L-Mesitran Foam: Evaluation of a New Wound Care Product |
title_sort | l-mesitran foam: evaluation of a new wound care product |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023218/ https://www.ncbi.nlm.nih.gov/pubmed/35464882 http://dx.doi.org/10.1155/2022/4833409 |
work_keys_str_mv | AT mthantisegametsimaryjane lmesitranfoamevaluationofanewwoundcareproduct AT pellegloria lmesitranfoamevaluationofanewwoundcareproduct AT cremersnielsaj lmesitranfoamevaluationofanewwoundcareproduct |